Target Name: MIR190B
NCBI ID: G100126346
Review Report on MIR190B Target / Biomarker Content of Review Report on MIR190B Target / Biomarker
Other Name(s): hsa-miR-190b-5p | mir-190b | hsa-mir-190b | MIRN190B | hsa-miR-190b-3p | MicroRNA 190b | microRNA 190b

MIR190B: A Potential Drug Target and Biomarker


In recent years, microRNAs (miRNAs) have gained significant attention as potential therapeutic targets and biomarkers for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. One such miRNA that has emerged as a promising candidate is MIR190B. This article delves into the role of MIR190B as a drug target and biomarker, highlighting its potential applications in diagnosis, prognosis, and therapy.

What are microRNAs?

Before discussing MIR190B, it is essential to understand the basics of microRNAs. MiRNAs are small, non-coding RNA molecules that play pivotal roles in gene expression regulation. These molecules act as post-transcriptional regulators by binding to messenger RNA (mRNA), leading to mRNA degradation or translational repression. Through this mechanism, miRNAs modulate the expression of numerous genes involved in various cellular processes, making them crucial players in disease development and progression.

The Role of MIR190B in Cancer

MIR190B has been studied extensively in the context of cancer, where its dysregulation has been implicated in tumorigenesis, metastasis, and therapeutic resistance. Several studies have demonstrated that MIR190B acts as an oncogene, promoting tumor cell proliferation and survival in various cancer types, including breast, lung, and colorectal cancers. Moreover, increased levels of MIR190B have been associated with poor prognosis and reduced survival rates in cancer patients.

Targeting MIR190B for Cancer Therapy

Given its critical role in cancer progression, MIR190B has garnered attention as a potential therapeutic target. Researchers have explored several strategies to inhibit MIR190B, including the use of antisense oligonucleotides and small interfering RNAs (siRNAs). In preclinical studies, these approaches have shown promising results, with MIR190B inhibition leading to reduced tumor growth and enhanced sensitivity to chemotherapy.

MIR190B as a Biomarker in Disease Diagnosis and Prognosis

Apart from its potential as a therapeutic target, MIR190B also holds promise as a biomarker for disease diagnosis and prognosis. The differential expression of MIR190B has been observed in various cancers, suggesting its potential as a diagnostic tool. For instance, elevated levels of MIR190B have been associated with breast cancer, allowing for the development of non-invasive tests for early detection. Similarly, its expression levels have been correlated with the aggressiveness of prostate cancer and the treatment response in colorectal cancer patients.

Challenges and Future Directions

Although MIR190B shows immense potential as a drug target and biomarker, several challenges need to be overcome for its successful translation into clinical practice. Firstly, the lack of standardized protocols and techniques for miRNA profiling hampers reliable and reproducible results. Additionally, the development of efficient delivery systems for miRNA-based therapeutics remains an obstacle. However, ongoing research and advancements in these areas provide hope for overcoming these challenges.


MIR190B, a small RNA molecule, has emerged as a potential drug target and biomarker in various diseases, particularly cancer. Its dysregulation has been implicated in cancer progression, making it an attractive candidate for therapeutic interventions. Additionally, MIR190B shows promise as a biomarker for disease diagnosis and prognosis. Nonetheless, further research is needed to elucidate its precise mechanisms and validate its clinical utility. With continued efforts, MIR190B may pave the way for improved therapeutic strategies and precision medicine approaches in the future.

Protein Name: MicroRNA 190b

The "MIR190B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR190B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28